NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a growing home health care organization, announces that the Company has issued stock options. The Company has granted 950,000 incentive stock options to directors, officers and senior employees of the Company. The stock options are exercisable for a period of 10 years at an exercise price of CAD$0. ...

BREAKING: Carvana, Comfort Systems, CRH To Join S&P 500 Today's Spotlight MarketSurge Cyber Week Sale This week, save over 80% on MarketSurge—get 2 months of unlimited access for only $59.95. Free webinar: Prepare Your 2026 Portfolio Learn how to read key market signals and position your portfolio for the upcoming year. December Webinar Sale Health care play BrightSpring Health Services (BTSG), a recent initial public offering, pulled back from record highs this past week and settled into a recent buy zone. ...

Core Insights - Extendicare Inc. announced the acquisition of CBI Home Health for a cash purchase price of $570 million, which will enhance its service offerings and strengthen its market position in home health care [2][3][11] - The acquisition is expected to generate significant synergies and improve financial metrics, including a projected 20% accretion in AFFO per share and 15% in earnings per share [9][11] Acquisition Details - The acquisition will be funded through a combination of a $264.5 million upsizing to Extendicare's existing credit facility and a $200 million bought deal private placement equity offering [5][15][16] - CBI Home Health delivered over 10 million hours of care annually across seven provinces, with a revenue of approximately $477.9 million and an Adjusted EBITDA of $61.9 million for the twelve months ended July 31, 2025 [10][11] Financial Metrics - The acquisition price represents an estimated purchase price multiple of 9.4x CBI Home Health's Adjusted EBITDA, which could improve to approximately 8.4x after accounting for expected synergies of about $7.4 million [11][12] - Extendicare's pro forma total debt to Adjusted EBITDA ratio is projected to be 3.3x as of September 30, 2025, post-acquisition [8][15] Strategic Rationale - The acquisition aligns with Extendicare's growth strategy by enhancing its capabilities in home health care and expanding its geographic footprint, particularly in Western Canada [6][9] - The combination of ParaMed and CBI Home Health is expected to improve access to community-based care and leverage technology for better customer experience and cost efficiencies [6][9] Offering Details - Extendicare plans to issue 10.64 million common shares at a price of $18.80 per share, aiming for gross proceeds of approximately $200 million from the private placement [5][17] - The closing of the offering is anticipated around December 3, 2025, subject to regulatory approvals [17]

Acquisition Overview - Extendicare is acquiring CBI Home Health for $570 million[37, 94] - The acquisition is expected to be accretive to Extendicare's AFFO per share by 15% and earnings per share by 9%[34] - Post-synergies, the accretion is expected to increase to 20% for AFFO per share and 15% for earnings per share[34] - CBI Home Health's revenue for the twelve months ended July 31, 2025, was $478 million, with adjusted EBITDA of $61.9 million[34, 35, 87] - The purchase price represents 9.4x EV/Adjusted EBITDA pre-synergies and 8.4x post-synergies[94] Financing and Leverage - The acquisition will be funded through a combination of $26 million cash on hand, $200 million equity private placement, $205 million term loan, and $154 million revolver[37, 98] - Pro forma total debt to Adjusted EBITDA is expected to be 3.3x at transaction close[99] Extendicare's Business Segments - ParaMed, Extendicare's home health care segment, delivers over 13.5 million hours of home health care annually across 3 provinces[28, 40] - Extendicare operates 59 fully owned long-term care homes and manages 40 homes, representing approximately 7% of the Canadian market and 13% of the Ontario market[28] - Extendicare's managed services segment serves approximately 152,000 third-party and JV beds[42, 71] Market and Growth - The number of Canadians aged 85+ is projected to double by 2036 and triple by 2051[48] - ParaMed's care volumes grew by more than 10% in 2024 vs 2023 and increased 13% YTD Q3 2025 vs YTD Q3 2024[51] - Extendicare has a joint venture with Axium Infrastructure to redevelop LTC homes, with six homes under construction and 1,408 new beds replacing 1,097 Class C beds[77, 78]

Core Viewpoint - Nova Leap Health Corp. reported record financial results for Q3 2025, achieving significant growth in revenues and Adjusted EBITDA, reflecting strong operational performance and strategic execution [2][4][7]. Financial Performance - Q3 2025 revenues reached $8,264,326, marking a 3% increase from Q2 2025 and a 29% increase from Q3 2024 [2]. - Adjusted EBITDA for Q3 2025 was $670,706, up 16.1% from Q2 2025 and 76.9% from Q3 2024 [4]. - The gross profit margin was 39.6% in Q3 2025, compared to 40.2% in Q2 2025 and 38.0% in Q3 2024 [10]. Record Achievements - The company set nine financial records in Q3 2025, including consolidated revenues, gross margin, and Adjusted EBITDA [5][7]. - Canadian and U.S. operating segments also achieved record revenues, gross margins, and Adjusted EBITDA [5]. Operational Insights - The company has established a new performance benchmark with Adjusted EBITDA averaging over $400,000 quarterly from Q2 2023 to Q1 2025, now reset to higher levels [8]. - The company generated income from operating activities of $418,553 in Q3 2025, an increase from previous quarters [10]. Financial Position - As of September 30, 2025, the company had available cash of $1,571,716 and access to an unutilized revolving credit facility of $1,077,509 [10]. - Total demand loans and promissory notes outstanding were $2,300,800, resulting in a leverage ratio of 1.18 times to trailing twelve-month Adjusted EBITDA [10]. Strategic Focus - The company emphasizes disciplined growth, profitability, and long-term value creation, supported by a strong balance sheet and positive operating cash flow [9][10].

Financial Data and Key Metrics Changes - Consolidated net revenue totaled $263.6 million, an increase of $10 million or 3.9% year over year [17] - Consolidated adjusted EBITDA was $27 million, reflecting a sequential increase of $0.1 million or 0.4% and a year-over-year increase of $2.5 million or 10.2% [18] - Net debt to adjusted EBITDA leverage ratio improved to 3.9 times, down from 5.4 times in Q4 2023 [15][26] Business Line Data and Key Metrics Changes - Home Health total admissions increased by 3.6% year over year, with a census increase of 3.7% [7] - Hospice segment revenue reached $63.1 million, reflecting a year-over-year growth of 20% [22] - Home health adjusted EBITDA totaled $33.9 million, a decrease of 7.1% year over year [20] Market Data and Key Metrics Changes - Fee-for-Service Medicare census stabilized with a decline of only 1.4% year over year, compared to a 14.1% decline in Q3 2024 [8] - Non-Medicare admissions increased by 10.4%, contributing to a 2.8% increase in non-Medicare revenue per visit year over year [8] Company Strategy and Development Direction - The company is focused on mitigating pricing headwinds from the CMS 2026 Home Health Final Rule through various strategies [29] - The de novo strategy is positively impacting total growth, with plans to open a total of 10 de novos in 2025 [11] - The company aims to improve operational efficiency and reduce costs to strategically invest in people and technology [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning within the industry, citing experienced leaders and innovative technology [13] - The company anticipates continued growth momentum into Q4 and has updated full-year guidance for revenue and adjusted EBITDA [27][28] - Management highlighted the importance of maintaining staffing productivity to offset wage inflation [44] Other Important Information - The company has successfully reduced overall bank debt by $15.5 million during the quarter, with a total reduction of $100 million since Q4 2023 [26] - Home office expenses improved to 9.1% of revenues, down from 9.9% in the prior quarter, reflecting effective cost management initiatives [25] Q&A Session Summary Question: Can you provide some color on the rate increase from the new payer innovation contract in November? - Management indicated that they cannot disclose specific updates but mentioned that more regional agreements will be coming up for renewal in the next year [33] Question: Can you provide details on the G&A expense reduction? - Management noted that the reduction came from headcount adjustments and efficiencies gained by insourcing capabilities, estimating that $1 million-$1.5 million of the improvement is durable [34] Question: What seasonal factors drive hospice performance at the end of the year? - Management acknowledged that holiday times can be unpredictable, with patients often delaying decisions until after the holidays [38] Question: How long is the typical recontracting cycle for payer innovation contracts? - Management stated that most contracts are typically three years, with some being two years [40] Question: How is the company managing labor costs and wage inflation? - Management reported an uptick in the applicant pool for nursing and therapy, with wage inflation expected to normalize around 3% [44]

Core Insights - The Pennant Group, Inc. reported a GAAP diluted earnings per share of $0.17 and an adjusted diluted earnings per share of $0.30 for Q3 2025, reflecting strong operational performance across its segments [1][4][6]. Financial Performance - Total revenue for Q3 2025 was $229.0 million, a 26.8% increase from the prior year [4]. - Net income for Q3 2025 was $6.1 million, a slight decrease of 2.0% compared to the previous year [4]. - Adjusted net income for Q3 2025 was $10.4 million, up 27.6% year-over-year [4]. - Consolidated Adjusted EBITDAR for Q3 2025 was $29.3 million, a 12.8% increase from the prior year [4]. - Consolidated Adjusted EBITDA for Q3 2025 was $17.3 million, reflecting a 14.5% increase year-over-year [4]. Segment Performance - Home Health and Hospice Services segment revenue was $173.6 million, a 27.9% increase from the prior year [4]. - Senior Living Services segment revenue was $55.5 million, up 23.2% year-over-year [4]. - Total home health admissions increased by 36.2% to 20,426 in Q3 2025 [4]. - Hospice average daily census rose by 17.4% to 4,044 [4]. - Senior Living average occupancy increased by 180 basis points to 80.9% [4]. Acquisition and Expansion - The company completed the acquisition of 54 home health, hospice, and home care operations from UnitedHealth Group and Amedisys on October 1, 2025, marking the largest transaction in its history [5]. - This acquisition is expected to enhance the company's operational capabilities and expand its market presence in the Southeast [5]. Guidance and Expectations - The company updated its 2025 annual guidance, projecting total revenue between $911.4 million and $948.6 million [6]. - Full-year adjusted earnings per diluted share is anticipated to be between $1.14 and $1.18, representing a growth of 23.4% from 2024 [7]. - The guidance reflects strong operational performance and the impact of the recent acquisition [8].

Core Insights - The announcement of The Top 50 Women Chief Growth Officers for 2025 highlights the growing importance of the Chief Growth Officer role in shaping business strategy and driving sustainable growth [1][5] Group 1: Recognition of Leaders - Jasmin Valdez, Chief Growth Officer of ProHealth Home Care, is recognized for her extensive experience in healthcare and her role in improving market position and managing marketing activities [2] - Amy Katz, Chief Growth Officer at PACE Southeast Michigan, is acknowledged for her leadership in business development and program expansion, enhancing community-based care for seniors [3] - Amanda Custodio, Chief Growth Officer of BMO Wealth Management, is celebrated for providing strategic direction for growth initiatives across various financial services [4] Group 2: Broader Impact - The initiative aims to celebrate the accomplishments of women leaders in executive roles, inspiring others to pursue leadership positions [5][7] - Women We Admire circulates content to over 70,000 individuals and businesses, emphasizing the recognition of exceptional women across various fields [7]

Core Insights - Nova Leap Health Corp. will present its record second-quarter financial results at the Planet MicroCap Showcase on October 22-23, 2025, highlighting operational momentum and disciplined growth [2][3] Company Overview - Nova Leap is a home health care services company operating in a rapidly growing industry in the U.S. and Canada, focusing on individual and family-centered care, particularly for dementia patients [4] - The company has achieved notable rankings, including 42 on the 2021 Report on Business list of Canada's Top Growing Companies and 2 in 2020 [4] Event Details - Chris Dobbin, President & CEO, will deliver a presentation via webcast on October 22, 2025, at 11:30 am EST, followed by one-on-one investor meetings [3] - The event will feature a live webcast and an archive of the presentation available on the Planet MicroCap Showcase website [3] Market Position - With the increasing demand for home-based care, Nova Leap is positioned for continued profitable growth and expansion of its care services across North America [3]

Core Insights - The Pennant Group, Inc. has acquired certain operations from UnitedHealth Group for $146.5 million, which includes home health, hospice, and personal care services in Tennessee, Georgia, and Alabama [1][2]. Acquisition Details - The acquisition involves 54 locations with combined revenues of $189.3 million over the trailing twelve months [2]. - Approximately two-thirds of the revenue from the acquired agencies is related to home health services, while one-third is from hospice services [3]. Strategic Importance - This acquisition marks a strategic expansion for Pennant into the Southeast region, enhancing its operational footprint and growth potential [4]. - The company has established a transition services agreement with UnitedHealth to ensure a smooth integration process [3]. Leadership Perspective - Pennant's CEO, Brent Guerisoli, emphasized the strategic nature of this move and the company's commitment to operational excellence and leadership in the industry [4]. - COO John Gochnour highlighted the quality of the acquired teams and their local ties, which will contribute to the success of the integration [4]. Future Growth Plans - The company intends to continue pursuing growth opportunities in the home health, hospice, and senior living sectors, focusing on strategic and underperforming operations [4].